PartnershipJun 17, 2026, 09:28 AM
Cosmos Health Secures 5-Year Contract to Manufacture 2.86M Pharma Units
AI Summary
Cosmos Health, through its wholly owned subsidiary Cana Laboratories S.A., has entered into a five-year contract manufacturing agreement with Pharmex S.A. Cana will produce three pharmaceutical products, including BETAFUSIN®, BOTAFEX®, and BUDESODERM®, at its EU-GMP-licensed facility. The agreement covers a combined volume of approximately 2.86 million units over the five-year term. This deal reinforces Cosmos Health's position as a contract manufacturer, supports higher utilization of its EU manufacturing capacity, and is expected to strengthen recurring revenue from its higher-margin contract manufacturing activities.
Key Highlights
- Cana Laboratories, a Cosmos Health subsidiary, signed a five-year contract manufacturing agreement with Pharmex S.A.
- Agreement covers production of three pharmaceutical products: BETAFUSIN®, BOTAFEX®, and BUDESODERM®.
- Total combined volume of approximately 2.86 million units over the five-year term.
- BETAFUSIN® volume: 450,000 annual units, 2,250,000 five-year total.
- BOTAFEX® volume: 65,000 annual units, 325,000 five-year total.
- BUDESODERM® volume: 57,000 annual units, 285,000 five-year total.
- Reinforces Cosmos Health's role as a contract manufacturer and supports higher EU manufacturing capacity utilization.
- Aims to deepen long-term manufacturing partnerships and strengthen recurring revenue from higher-margin activities.
Price Impact
More from COSM